retatrutide triple agonist clinical trial Breaking: New data just released. TRIUMPH-1 study results on the agonist. Eli Lilly's trial on Retatrutide (triple compound). 80 weeks. Phase 3 data. The results: At 12mg retatrutide what is retatrutide clinical

(10) These are reasonable additions to a BPC-157 protocol rather than replacements

Fat mobilization improves

A 2025 post-hoc analysis of the SURMOUNT trial found tirzepatide produced approximately 20% weight loss in postmenopausal women, with a 20cm reduction in waist circumference, consistent with results in premenopausal women

Most children do very well with outdoor activities and exercise

Chronic sympathetic dominance (the "fight-or-flight" state) maintains cortisol elevation, which directly suppresses secretory IgA your gut's primary antibody defence against Candida

It makes it an adjunct with a plausible mechanism and thin outcome data, delivered inside a supervised programme